1. Introduction
===============

Cyanobacteria represent a rich source of bioactive compounds, many of which remain unexplored. To date, antibacterial, antiviral, antifungal, anticancer, immunosuppressive, protease inhibitory, and other pharmacological properties have been described for the secondary metabolites isolated from these microorganisms \[[@B1-marinedrugs-13-03892],[@B2-marinedrugs-13-03892],[@B3-marinedrugs-13-03892],[@B4-marinedrugs-13-03892],[@B5-marinedrugs-13-03892],[@B6-marinedrugs-13-03892],[@B7-marinedrugs-13-03892]\]. Structurally, these compounds are primarily of a peptide nature \[[@B1-marinedrugs-13-03892],[@B3-marinedrugs-13-03892],[@B8-marinedrugs-13-03892]\] and are mainly synthesized via non-ribosomal peptide synthetases (NRPS) or a combination of NRPS and the polyketide synthetase (NRPS/PKS) \[[@B3-marinedrugs-13-03892]\]. Most of these cyanopeptides can be grouped into seven families based on conserved substructures \[[@B3-marinedrugs-13-03892]\]: anabaenopeptins, cyanopeptolins, cyclamides, microcystins, microginins, aeruginosins, and microviridins. Particular interest arises from cyanobacteria growing in extreme environments, since these underexplored habitats may harbor a microbial diversity able to synthesize a unique variety of secondary metabolites \[[@B9-marinedrugs-13-03892]\].

The Atlantic Forest is a continental biome that extends primarily along the Atlantic coast of Brazil and also includes small portions of Argentina and Paraguay \[[@B10-marinedrugs-13-03892],[@B11-marinedrugs-13-03892]\]. Considered one of the richest regions in the world in terms of biodiversity and endemism, this forest is also one of the most threatened regions \[[@B12-marinedrugs-13-03892]\]. With respect to the microorganisms that inhabit this region, little is known \[[@B13-marinedrugs-13-03892]\]. Particularly, referring to cyanobacteria, the available information is typically focused on diversity and descriptions of species \[[@B14-marinedrugs-13-03892],[@B15-marinedrugs-13-03892],[@B16-marinedrugs-13-03892],[@B17-marinedrugs-13-03892]\] and scarce information about secondary metabolite production is available \[[@B18-marinedrugs-13-03892]\]. Cyanobacteria inhabiting the phyllosphere (leaf surface) are exposed to hostile conditions such as low availability of nutrients, large temperature range, osmotic stress, and high incidence of ultraviolet rays \[[@B19-marinedrugs-13-03892]\], representing a little explored community of extremophilic organisms with potential for production of novel bioactive compounds.

Due to the development in instrumentation and technology, mass spectrometry (MS) has rapidly become a fundamental tool for characterizing large biomolecules such as proteins and peptides \[[@B20-marinedrugs-13-03892],[@B21-marinedrugs-13-03892]\]. The development of electrospray ionization (ESI) and matrix-assisted laser desorption/ionization (MALDI) in conjunction with the introduction of multi-stage and hybrid analyzers was decisive for the success of MS analysis of biomolecules \[[@B20-marinedrugs-13-03892]\]. Time-of-flight (TOF) is one type of mass analyzer that finds wide application in this field and can provide high-resolution spectra for protein and peptides. Particularly when combined with other types of mass analyzer, such as the quadrupole mass analyzer forming the hybrid quadrupole time-of-flight (QTOF), valuable peptide or amino acid sequence information can also be obtained. Liquid chromatography (LC) is a typical inlet method for MS analysis and provides an extra dimension of separation. LC can be coupled with ESI (online/offline) or MALDI (offline). Matrix-assisted laser desorption ionization-time-of-flight-mass spectrometry (MALDI-TOF-MS) has been employed in the identification of many known and new cyanopeptides directly from cyanobacteria \[[@B22-marinedrugs-13-03892],[@B23-marinedrugs-13-03892],[@B24-marinedrugs-13-03892],[@B25-marinedrugs-13-03892],[@B26-marinedrugs-13-03892]\]. Applications of liquid chromatography (LC) coupled to quadrupole time-of-flight mass spectrometry (QTOF-MS) have also been reported \[[@B27-marinedrugs-13-03892],[@B28-marinedrugs-13-03892],[@B29-marinedrugs-13-03892]\].

In this study, the peptide profiles of 40 strains of cyanobacteria isolated from the phyllosphere of four native species of plants in the coastal forest of Southeastern Brazil \[[@B30-marinedrugs-13-03892]\] ([Table 1](#marinedrugs-13-03892-t001){ref-type="table"}) were investigated using LC-ESI-Q-TOF-MS with positive ion detection and revealed a high production potential in the heterocytous strains. Accurate masses and isotope patterns for both precursor and product ions were used to propose the planar structures of the observed peptides.

marinedrugs-13-03892-t001_Table 1

###### 

Cyanobacteria included in the present study.

  Strain    Order                     Family              Genus ^a^                 Source ^b^
  --------- ------------------------- ------------------- ------------------------- ------------
  CENA353   Chroococcales             Xenococcaceae       *Chroococcidiopsis* sp.   *Mn*-SV
  CENA367   *Chroococcidiopsis* sp.   *Ee*-SV                                       
  CENA351   Hydrococcacceae           *Pleurocapsa* sp.   *Mn*-SV                   
  CENA350   Pseudanabaenales          Pseudanabaenaceae   *Leptolyngbya* sp.        *Mn*-SV
  CENA355   *Leptolyngbya* sp.        *Mn*-SV                                       
  CENA359   \-                        *Gg*-Pi                                       
  CENA364   *Leptolyngbya* sp.        *Gg*-Pi                                       
  CENA370   *Oculatella* sp.          *Ee*-SV                                       
  CENA374   *Leptolyngbya* sp.        *Ee*-Pi                                       
  CENA372   *Leptolyngbya* sp.        *Ee*-Pi                                       
  CENA375   *Leptolyngbya* sp.        *Ee-Pi*                                       
  CENA377   *Leptolyngbya* sp.        *Ee-Pi*                                       
  CENA378   *Leptolyngbya* sp.        *Ee-Pi*                                       
  CENA384   \-                        *Go-Pi*                                       
  CENA385   \-                        *Go-Pi*                                       
  CENA387   *Leptolyngbya* sp.        *Go*-Pi                                       
  CENA354   Nostocales                Microchaetaceae     \-                        *Mn*-SV
  CENA352   Nostocaceae               *Nostoc* sp.        *Mn*-SV                   
  CENA356   *Nostoc* sp.              *Mn*-SV                                       
  CENA357   *Nostoc* sp.              *Gg-Pi*                                       
  CENA358   *Nostoc* sp.              *Gg-Pi*                                       
  CENA362   *Desmonostoc* sp.         *Gg-Pi*                                       
  CENA363   *Desmonostoc* sp.         *Gg-Pi*                                       
  CENA365   *Desmonostoc* sp.         *Gg-Pi*                                       
  CENA368   *Nostoc* sp.              *Ee-SV*                                       
  CENA369   *Nostoc* sp.              *Ee-Pi*                                       
  CENA371   *Desmonostoc* sp.         *Ee-SV*                                       
  CENA373   *Nostoc* sp.              *Ee-SV*                                       
  CENA376   *Nostoc* sp.              *Ee-Pi*                                       
  CENA379   *Nostoc* sp.              *Ee-SV*                                       
  CENA380   *Desmonostoc* sp.         *Ee-SV*                                       
  CENA383   *Desmonostoc* sp.         *Go-Pi*                                       
  CENA386   *Desmonostoc* sp.         *Go-Pi*                                       
  CENA388   *Nostoc* sp.              *Go-Pi*                                       
  CENA389   *Nostoc* sp.              *Go-Pi*                                       
  CENA360   Nostocales                Scytonemataceae     *Brasilonema* sp.         *Gg-Pi*
  CENA361   *Brasilonema* sp.         *Gg-Pi*                                       
  CENA366   *Brasilonema* sp.         *Gg-Pi*                                       
  CENA381   *Brasilonema* sp.         *Ee-Pi*                                       
  CENA382   *Brasilonema* sp.         *Ee-Pi*                                       

^a^ Identity criteria for the determination of genus was established in ≥95% when comparing with 16S rRNA genes between the surveyed cyanobacteria and the sequences deposited in the *GenBank* (NBCI). ^b^ Plant species: *Ee*: *Euterpe edualis*; *Mn*: *Merostachys neesii*; *Gg*: *Garcinia gardneriana*; *Go*: *Guapira opposita*. Localization Pi: Picinguaba; SV: Santa Virginia sites, in Parque Estadual da Serra do Mar, São Paulo, Brazil.

marinedrugs-13-03892-t002_Table 2

###### 

LC-QTOF data of the peptides from the hydromethanolic extracts of cyanobacteria isolated from the Brazilian Atlantic Forest.

  No                  Compound ^a^                                     RT (min)   \[M + H\]^+^ *m/z*   Molecular Formula ^b^   Error (ppm)   mSigma   Detected in Strains CENA   Reference                                             
  ------------------- ------------------------------------------------ ---------- -------------------- ----------------------- ------------- -------- -------------------------- ----------- ----- ----- ----- ----- ----- ----- ----- ---------------------------------
  *aeruginosins*                                                                                                                                                                                                                       
  1                   Hpla-Leu-(Hex)-OHChoi-Agma                       17.2       753.4042             C~35~H~55~N~6~O~12~     −1.7          13.2     352                                          360         381   382               this study
  2                   Hpla-Leu-(Hex)Choi-Agma                          18.0       767.3828             C~35~H~55~N~6~O~13~     −1.6          2.1      352                        358               360         381   382               this study
  3                   Hpla-Leu-(Gluc)-OHChoi-Agma                      18.2       737.4044             C~35~H~55~N~6~O~11~     −1.2          2.2      352                        358               360         381   382               this study
  4                   Hpla-Leu-(Hex,But)-OHChoi-Agma                   20.0       823.4470             C~39~H~63~N~6~O~13~     −2.7          1.0      352                        358               360         381                     this study
  5                   Hpla-Leu-(Gluc,But)-OHChoi-Agma                  20.6       837.4253             C~39~H~61~N~6~O~14~     1.0           13.0     352                        358               360                                 this study
  6                   Hpla-Leu-(Hex,Hexan)-OHChoi-Agma                 22.5       851.4780             C~41~H~67~N~6~O~13~     2.3           2.0      352                        358         369   360   361   381   382               this study
  7                   Hpla-Leu-(Gluc,Hexan)-OHChoi-Agma                23.1       865.4560             C~41~H~65~N~6~O~14~     −0.8          2.8      352                        358         369   360   361   381   382               \[[@B37-marinedrugs-13-03892]\]
  8                   Hpla-*N*MeLeu-(Gluc,Hexan)-OHChoi-Agma           23.8       879.4717             C~42~H~67~N~6~O~14~     −0.9          18.9     352                                          360                                 this study
  9                   Hpla-Leu-(Gluc,Hep)-OHChoi-Agma                  25.6       879.5078             C~43~H~71~N~6~O~13~     −0.5          10.7                                358               360         381                     this study
  10                  Pla-dehydroLeu-(Gluc,Hexan)-OHChoi-Agma          25.1       849.4596             C~41~H~65~N~6~O~13~     0.9           9.1      352                        358               360         381                     this study
  11                  Hpla-Leu-(Gluc,Oct)-OHChoi-Agma                  26.1       893.4872             C~43~H~69~N~6~O~14~     −0.6          0.8      352                        358               360         381   382               this study
  *anabaenopeptins*                                                                                                                                                                                                                    
  12                  Lys-CO\[Lys-Ile-Hph-*N*MeAsn-Phe\]               24.0       850.4818             C~43~H~64~N~9~O~9~      0.4           7.2                                                                                 386   this study
  13                  Arg-CO\[Lys-Ile-Hph-*N*MeAsn-Phe\]               24.4       878.4864             C~43~H~64~N~11~O~9~     2.2           11.0                                                                                386   this study
  14                  Lys-CO\[Lys-Ile-MeHph-*N*MeAsn-Phe\]             24.8       864.4972             C~44~H~66~N~9~O~9~      0.7           1.8                                                                                 386   this study
  15                  Arg-CO\[Lys-Ile-MeHph-*N*MeAsn-Phe\]             25.2       892.5023             C~44~H~66~N~11~O~9~     1.8           4.0                                                                                 386   this study
  16                  Lys-CO\[Lys-Ile-EtHph-*N*MeAsn-Phe\]             26.0       878.5122             C~45~H~68~N~9~O~9~      1.4           2.0                                                                                 386   this study
  17                  Arg-CO\[Lys-Ile-EtHph-*N*MeAsn-Phe\]             26.3       906.5196             C~45~H~68~N~11~O~9~     −0.4          5.0                                                                                 386   this study
  18                  Phe-CO\[Lys-Val-Hty-MeAla-Hty\]                  31.1       858.4405             C~45~H~60~N~7~O~10~     −1.1          2.5      352                                                                              this study
  19                  Phe-CO\[Lys-Ile-Hty-MeAla-Hty\]                  31.8       872.4544             C~46~H~62~N~7~O~10~     1.0           5.9      352                                                                              this study
  20                  Val-CO\[Lys-Ile-Trp-MeAla-Phe\]                  34.1       803.4425             C~42~H~59~N~8~O~8~      3.2           5.2                                                   360               382               this study
  21                  Val-CO\[Lys-Ile-Trp-MeAla-Phe\]                  34.6       803.4417             C~42~H~59~N~8~O~8~      4.1           9.6                                                   360               382               this study
  22                  Leu-CO\[Lys-Ile-MeHph-*N*MeAsn-Phe\]             34.8       849.4872             C~44~H~65~N~8~O~9~      −0.4          3.5                                                                                 386   this study
  23                  Phe-CO\[Lys-Val-Hph-MeAla-Hty\]                  35.0       842.4416             C~45~H~60~N~7~O~9~      −3.1          1.9      352                                                                              this study
  24                  Phe-CO\[Lys-Ile-Hph-MeAla-Hty\]                  35.8       856.4561             C~46~H~62~N~7~O~9~      5.0           1.6      352                                                                              this study
  25                  Phe-CO\[Lys-Ile-MeHph-*N*MeAsn-Phe\]             35.4       883.4695             C~47~H~63~N~8~O~9~      2.0           12.6                                358                                                   this study
  26                  Leu-CO\[Lys-Ile-EtHph-*N*MeAsn-Phe\]             36.1       863.5028             C~45~H~67~N~8~O~9~      0.3           4.0                                                                                 386   this study
  27                  Phe-CO\[Lys-Ile-EtHph-*N*MeAsn-Phe\]             36.7       897.4858             C~48~H~65~N~8~O~9~      1.2           3.3                                 358                                                   this study
  *cyanopeptolins*                                                                                                                                                                                                                     
  28                  Mdhp-Gln\[Thr-Leu-Ahp-Leu-*N*Me-Cl-Tyr-Leu\]     27.7       1002.5031            C~48~H~73~ClN~9~O~12~   3.0           12.0                                                                          371   386   this study
  29                  AcPro-Gln\[Thr-Leu-Ahp-Val-*N*Me-OMe-Tyr-Val\]   28.9       984.5381             C~48~H~74~N~9~O~13~     2.0           13.5                                                                                386   this study
  30                  AcPro-Gln\[Thr-Leu-Ahp-Val-*N*Me-Cl-Tyr-Val\]    29.1       1004.4831            C~47~H~71~ClN~9~O~13~   2.3           5.9                                                                           371   386   this study
  31                  AcPro-Gln\[Thr-Leu-Ahp-Leu-*N*Me-Tyr-Leu\]       29.9       998.5531             C~49~H~76~N~9~O~13~     2.7           9.9                                                                                 386   this study
  32                  AcPro-Gln\[Thr-Leu-Ahp-Val-*N*Me-Cl-Tyr-Leu\]    30.5       1018.5011            C~48~H~73~ClN~9~O~13~   0.0           4.8                                                                           371   386   this study
  33                  AcPro-Gln\[Thr-Leu-Ahp-Val-*N*Me-OMe-Tyr-Val\]   31.0       984.5398             C~48~H~74~N~9~O~13~     0.3           18.4                                                                          371   386   this study
  34                  AcPro-Gln\[Thr-Leu-Ahp-Leu-*N*Me-Cl-Tyr-Leu\]    31.6       1032.5170            C~49~H~75~ClN~9~O~13~   0.3           4.9                                                                           371   386   this study
  35                  AcPro-Gln\[Thr-Leu-Ahp-Val-*N*Me-OMe-Tyr-Leu\]   32.1       998.5549             C~49~H~76~N~9~O~13~     0.8           15.8                                                                          371   386   this study
  36                  AcPro-Gln\[Thr-Leu-Ahp-Leu-*N*Me-OMe-Tyr-Val\]   32.7       998.5564             C~49~H~76~N~9~O~13~     −0.7          2.6                                                                           371   386   this study
  37                  AcPro-Gln\[Thr-Leu-Ahp-Leu-*N*Me-OMe-Tyr-Leu\]   33.9       1012.5737            C~50~H~78~N~9~O~13~     2.4           8.0                                                                           371   386   this study
  38                  PrPro-Gln\[Thr-Leu-Ahp-Leu-*N*Me-OMe-Tyr-Leu\]   35.2       1026.5858            C~51~H80N~9~O~13~       1.1           26.7                                                                          371   386   this study

^a^ Hpla: hydroxy-phenyl lactic acid; Pla: phenyl lactic acid; OH: hydroxy; Hex: hexose; Gluc: glucuronic acid; But: butanoic acid; Hexan: hexanoic acid; Hep: heptanoic acid; Oct: octanoic acid; Me: methyl; Et: ethyl; \[\] cyclo; Ac: acetyl; Pr: propanoyl; Mdhp: methyl-dehydroproline; *N*Me-Cl-Tyr: *N-*methyl-3-chloro-tyrosine; *N*Me-OMe-Tyr: *N-*methyl-*O*-methyl-tyrosine.

2. Result and Discussion
========================

The peptide profiles of the 40 strains isolated from the Atlantic Forest (CENA350-389) were investigated using LC/DAD/ESI/QTOF/MS/MS. As an example, [Figure 1](#marinedrugs-13-03892-f001){ref-type="fig"} shows the chromatographic profiles of two strains: one *Brasilonema* sp. and one *Desmonostoc* sp. The retention times (RT), protonated molecules (\[M + H\]^+^), molecular formula provided for the experimental *m/z*, and error and millisigma (mSigma) values for the major peaks are summarized in [Table 2](#marinedrugs-13-03892-t002){ref-type="table"}. Mass accuracy was below 5 ppm for all the detected compounds. Peak identification was performed based on the data presented in [Table 2](#marinedrugs-13-03892-t002){ref-type="table"}, [Table 3](#marinedrugs-13-03892-t003){ref-type="table"}, [Table 4](#marinedrugs-13-03892-t004){ref-type="table"}, [Table 5](#marinedrugs-13-03892-t005){ref-type="table"}, [Table 6](#marinedrugs-13-03892-t006){ref-type="table"}, [Table 7](#marinedrugs-13-03892-t007){ref-type="table"}, [Table 8](#marinedrugs-13-03892-t008){ref-type="table"}, [Table 9](#marinedrugs-13-03892-t009){ref-type="table"}, [Table 10](#marinedrugs-13-03892-t010){ref-type="table"}, [Table 11](#marinedrugs-13-03892-t011){ref-type="table"}, [Table 12](#marinedrugs-13-03892-t012){ref-type="table"}, [Table 13](#marinedrugs-13-03892-t013){ref-type="table"} and [Table 14](#marinedrugs-13-03892-t014){ref-type="table"} and based on previously published data \[[@B23-marinedrugs-13-03892],[@B24-marinedrugs-13-03892],[@B26-marinedrugs-13-03892],[@B31-marinedrugs-13-03892],[@B32-marinedrugs-13-03892],[@B33-marinedrugs-13-03892],[@B34-marinedrugs-13-03892],[@B35-marinedrugs-13-03892],[@B36-marinedrugs-13-03892],[@B37-marinedrugs-13-03892],[@B38-marinedrugs-13-03892],[@B39-marinedrugs-13-03892],[@B40-marinedrugs-13-03892]\]. This approach allowed the elucidation of the planar structures of 38 peptides, including 10 new aeruginosins, 16 new anabaenopeptins, and 11 new cyanopeptolins. Among the surveyed strains the heterocytous strains *Nostoc* sp. CENA352, CENA358, and CENA369, *Brasilonema* sp. CENA360, CENA361, CENA381, and CENA382 and *Desmonostoc* sp. CENA386 and CENA371 were identified as producers of cyanopeptides. Cyanopeptides were not detected in the extracts of the remaining 31 cyanobacterial strains under our experimental conditions.

![Base Peak Chromatogram of the hydromethanolic extract of the strains (**a**) *Desmonostoc* sp. CENA386 and (**b**) *Brasilonema* sp. CENA358. Conditions as described in experimental section.](marinedrugs-13-03892-g001){#marinedrugs-13-03892-f001}

2.1. Aeruginosins
-----------------

Seven strains belonging to the orders Nostocales (*Nostoc* sp. CENA352, CENA358, and CENA369; and *Brasilonema* sp. CENA360, CENA361, CENA381, and CENA382) were found to produce aeruginosins (**1--11**). Aeruginosins are linear tetrapeptides that contain the unusual amino acid 2-carboxy-6-hydroxyoctahydroindol (Choi) in the central position and typically contain an arginine derivative at the *C*-terminus \[[@B3-marinedrugs-13-03892]\]. The *N*-terminal position is occupied by a 3-(4-hydroxyphenyl) lactic or phenyl lactic acid, which can be acetylated, brominated, chlorinated, or sulfonated \[[@B41-marinedrugs-13-03892],[@B42-marinedrugs-13-03892],[@B43-marinedrugs-13-03892],[@B44-marinedrugs-13-03892]\]. A small hydrophobic amino acid (leucine or isoleucine) is typically present in position 2. Additionally, hydroxylation, sulfation, and chlorination of the Choi moiety have also been observed \[[@B45-marinedrugs-13-03892]\]. These peptides are potent inhibitors of serine proteases, and this bioactivity is largely related to *C*-terminal modifications \[[@B46-marinedrugs-13-03892]\]. This family of compounds has been reported to be produced by cyanobacteria of the genera *Microcystis* \[[@B41-marinedrugs-13-03892],[@B42-marinedrugs-13-03892],[@B43-marinedrugs-13-03892],[@B44-marinedrugs-13-03892],[@B47-marinedrugs-13-03892]\], *Planktothrix* \[[@B24-marinedrugs-13-03892]\], *Nodularia* \[[@B48-marinedrugs-13-03892]\], and *Nostoc* \[[@B37-marinedrugs-13-03892]\].

The aeruginosins found in these extracts were characterized by closely related structures, most of which were common to both *Nostoc* and *Brasilonema* producer species. The most prominent peak detected in the MS chromatogram of these extracts (**7**) was assigned to the aeruginosin 865 (*m/z* 865.4565 \[M + H\]^+^) \[[@B37-marinedrugs-13-03892]\]. This compound, which was recently isolated from a terrestrial cyanobacterium belonging to *Nostoc* sp., was structurally characterized as containing both a fatty acid and a carbohydrate attached to the Choi moiety \[[@B37-marinedrugs-13-03892]\]. [Figure 2](#marinedrugs-13-03892-f002){ref-type="fig"} shows the product ion spectra of this aeruginosin. A collision energy of 70 eV was necessary to obtain a spectrum with abundant and intense product ions. Consistent with the existence of an agmatine (Agma) residue in the molecule, the *C*-terminal ions (*m/z* 588.3249, 412.2912, and 297.1989) and the corresponding satellite ions, which were produced via ammonia or water loss (*m/z* 571.2985, 395.2657, 279.1820, and 261.1717) dominated the spectrum. Additionally, the ions generated by the cleavage of the glycosidic acid and/or the ester bond established the sugar and the lipid acids as glucuronic acid and hexanoic acid, respectively. The presence of ions at *m/z* 18 u higher (*m/z* 156.1035 and 138.0866) than the diagnostic ions that are typically generated from the Choi residue (*m/z* 140 and 122) indicated the dihydroxylation of the indole ring in this amino acid and were key fragments for the detection of other aeruginosin congeners.

![Product ion spectrum for \[M + H\]^+^ of compound **7** and its predicted fragmentation pattern. Conditions as mentioned in the experimental section.](marinedrugs-13-03892-g002){#marinedrugs-13-03892-f002}

A total of 10 additional aeruginosins that shared conserved substructures (**1**--**6**, **8**--**11**) and yielded \[M + H\]^+^ at *m/z* 753.4042 (**1**), 767.3828 (**2**), 737.4044 (**3**), 823.4470 (**4**), 837.4253 (**5**), 851.4780 (**6**), 879.5078 (**8**), 879.5078 (**9**), 849.4596 (**10**), and 893.4872 (**11**) were identified as new congeners. The product ion spectra of these aeruginosins were similar to that of compound **7**, allowing us to elucidate their structures based on a comparison of spectra ([Table 3](#marinedrugs-13-03892-t003){ref-type="table"}, [Table 4](#marinedrugs-13-03892-t004){ref-type="table"} and [Table 5](#marinedrugs-13-03892-t005){ref-type="table"}).

marinedrugs-13-03892-t003_Table 3

###### 

Product ion spectra data for compounds **4**--**7**, **9**, and **11**.

  Product Ion Assignment ^a^                 4 (*m/z*)   5 (*m/z*)   6 (*m/z*)   7 (*m/z*)   9 (*m/z*)   11 (*m/z*)
  ------------------------------------------ ----------- ----------- ----------- ----------- ----------- ------------
  Leu immonium                               86.0967     86.0947     86.0907     86.0945     86.0906     86.0932
  OH-Choi immonium ion − H~2~O               138.0791    138.0866    138.0910    138.0912    138.0938    138.0903
  OH-Choi immonium ion                       156.1035    156.1035    156.1033    156.1026    \-          156.1031
  OH-Choi-Agma − NH~3~ − H~2~O + H           261.1693    261.1707    261.1799    261.1717    261.1791    261.1709
  OH-Choi-Agma − H~2~O + H                   279.1802    279.1801    279.1799    279.1820    279.1796    279.1828
  OH-Choi-Agma + H                           297.1925    297.1885    297.1882    297.1989    297.1880    297.1878
  (*R*^1^)-*O*-Choi-Agma + H − NH~3~         367.2348    367.2342    395.2672    395.2657    409.2803    423.2969
  (*R*^1^)-O-Choi-Agma + H                   384.2618    384.2617    412.2803    412.2912    426.3113    440.3226
  (*R*^1^, *R*^2^)-OH-Choi-Agma+ H − NH~3~   \- ^b^      543.2599    \-          571.2985    \-          599.3216
  (*R*^1^, *R*^2^)-OH-Choi-Agma + H          546.3176    560.2818    574.3454    588.3249    \-          616.3618
  Hpla-Leu-OHChoi-Agma + H − H~2~O           573.3423    573.3422    573.3417    573.3405    \-          573.3409
  Hpla-Leu-(*R*^1^)OH-Choi-Agma              661.3949    661.3909    689.4266    689.4250    703.4423    717.4543
  Hpla-Leu-(*R*^2^)OH-Choi-Agma              735.3952    749.3722    735.3945    749.3762    \-          \-
  Hpla-Leu-(*R*^1^, *R*^2^)-OH-Choi-Agma     823.4470    837.4253    851.4780    865.4560    879.5078    893.4872

^a^ *R*^1^ aliphatic lipid acid linked to hydroxyChoi in position 5: butanoic acid for compounds **4** and **5**; hexanoic acid for **6** and **7**; heptanoic acid for **9** and octanoic acid for **11**. *R*^2^ sugar linked to hydroxyChoi in position 6: hexose for compounds **4** and **6**; and glucuronoic acid for **5** and **7**; ^b^ - not detected.

marinedrugs-13-03892-t004_Table 4

###### 

Product ion spectra data for compounds **1**--**3**.

  Product Ion Assignment ^a^       1 (*m/z*)   3 (*m/z*)   2 \* (*m/z*)
  -------------------------------- ----------- ----------- --------------
  Leu immonium                     86.0908     86.0908     86.0967
  OH-Choi immonium ion − H~2~O     138.0867    138.0941    122.1066 \*
  OH-Choi immonium ion             156.0957    156.1036    140.1034 \*
  OH-Choi-Agma − NH~3~ − H~2~O     261.1592    \- ^b^      \-
  OH-Choi-Agma − NH~3~             297.1920    297.1928    263.1868 \*
  OH-Choi-Agma                     314.2143    314.2255    281.1914 \*
  *R*^2^-OH-Choi-Agma − NH~3~      \-          473.2107    443.2511 \*
  *R*^2^-OH-Choi-Agma              476.2717    490.2454    460.2740 \*
  Hpla-Leu-OHChoi-Agma             591.3360    591.3204    575.3841 \*
  Hpla-Leu-(*R*^2^)-OH-Choi-Agma   753.4042    767.3828    737.4044 \*

^a^ *R*^2^ sugar linked to hydroxyChoi in position 6: hexose for compounds **1** and **2**; and glucuronoic acid for **3**; ^b^ - not detected; \* structure lacking the 5-hydroxylation in Choi moiety.

marinedrugs-13-03892-t005_Table 5

###### 

Product ion spectra data for compounds **8** and **10**.

  Product Ion Assignment ^a^                  8 (*m/z*)   10 (*m/z*)
  ------------------------------------------- ----------- ------------
  *X* immonium                                100.1148    86.0906
  OH-Choi immonium ion − H~2~O                138.1248    138.0863
  OH-Choi immonium ion                        \- ^b^      156.0952
  OH-Choi-Agma − NH~3~ − H~2~O                261.1689    261.1687
  OH-Choi-Agma − H~2~O                        279.1797    279.1796
  OH-Choi-Agma − NH~3~                        297.1771    \-
  OH-Choi-Agma + H                            \-          \-
  (*R*^1^)-OH-Choi-Agma − NH~3~               395.2544    395.2659
  (*R*^1^)-OH-Choi-Agma + H                   412.2930    412.2928
  (*R*^1^, *R*^2^)-OH-Choi-Agma − NH~3~       571.3340    571.2881
  (*R*^1^, *R*^2^)-OH-Choi-Agma + H           588.3205    588.3238
  *Z*-*X*-(*R*^1^)OH-Choi-Agma + H            \-          673.4238
  *Z*-*X*-(*R*^1^)-OH-Choi-Agma + H           703.4398    \-
  *Z*-*X*-(*R*^1^, *R*^2^)-OH-Choi-Agma + H   879.4717    849.4596

^a^ *R*^1^: butanoic acid linked to hydroxyChoi in position 5; *R*^2^: glucuronoic acid linked to hydroxyChoi in position 6. *X* aminoacid in second position: methyl-leucine for compound **8** and leucine for **10**; *Z* phenyl alkanoic acid in position 1: hydroxylphenyl lactic acid for compound **8** and phenyllactic acid for **10**; ^b^ - not detected.

In this sense, a structure similar to that of aeruginosin 865 was proposed for compounds **5**, **9**, and **11** except for the fatty acid esterifying position 5 of the Choi moiety. In this position, butanoic, heptanoic, and octanoic acid were proposed for each compound, respectively. These changes were clearly evidenced by the sequence of ions containing the aforementioned fatty acids (*m/z* 384.2617, 543.2599, 560.2818, and 661.3909 for compound **5**; *m/z* 409.2803 and 703.4423 for compound **9**; and *m/z* 423.2969, 599.3216, 616.3618, and 717.4543 for compound **11**). On the other hand, structural differences between the pairs of compounds **4**, **5** and **6**, **7** were attributed to Choi-glycosylation.A similar product ion spectra, which differed only in the ions generated by the cleavage of the glycosidic bond (*m/z* 546.3176, 574.3454, and 735.3952/735.3945) suggested that the glucuronic acid in compounds **5** and **7** was replaced by a hexose in compounds **4** and **6**.

Compounds **1** and **3**, which also showed structures similar to compounds **4** and **6** and **5**, **7**, **9**, and **11**, respectively, were distinguished by the lack of fatty acids in their structures ([Table 4](#marinedrugs-13-03892-t004){ref-type="table"}). These peptides could be biosynthetic intermediates of the respective fatty acid-containing aeruginosins. Along with these compounds, an oxygen-deficient variant of compound **1** (**2**) was also detected; this structural difference was likely due to the absence of the Choi 5-hydroxylation.

Finally, two other structural variants of compound **7** were also detected (**8** and **10**). For compound **8**, methylation of the amino acid in the second position was suggested based on the mostly conserved product ion spectrum and the presence of a fragment ion at *m*/*z* 100.1148 (*N*MeLeu immonium). Similarly, for compound **10**, a phenyl lactic acid was proposed for the *N*-terminus instead of a hydroxyl-phenyl lactic acid ([Table 5](#marinedrugs-13-03892-t005){ref-type="table"}).

From a biomedical point of view, the pharmacological potential of these new aeruginosin variants must be evaluated. As mentioned above, aeruginosins typically exhibit antithrombotic activity, making these compounds interesting candidates for the development of anticoagulant drugs \[[@B46-marinedrugs-13-03892]\]. Additionally, all of these compounds are structurally similar to aeruginosin-865, which has exhibited remarkable anti-inflammatory activity \[[@B37-marinedrugs-13-03892]\]. Evaluations of the bioactivity of these compounds could provide insights into the structure-activity relationship of this class of aeruginosins.

2.2. Anabaenopeptins
--------------------

Fifteen compounds produced by *Nostoc* sp. CENA352, *Brasilonema* sp. CENA360, and *Desmonostoc* sp. CENA386 were characterized as new anabaenopeptin analogs (**12**--**27**). Protonated molecules in the mass range of anabaenopeptins and an important loss of the amino acid in the side-chain position were the diagnostic criteria used to classify these peptides \[[@B23-marinedrugs-13-03892]\]. These new anabaenopeptins were characterized based on empirical formulae, product ion spectra, and previously described sequences \[[@B23-marinedrugs-13-03892],[@B24-marinedrugs-13-03892],[@B26-marinedrugs-13-03892],[@B34-marinedrugs-13-03892],[@B36-marinedrugs-13-03892]\].

Anabaenopeptins are hexapeptides that contain a ring of five amino acids. Position 2 is always occupied by [d]{.smallcaps}-Lys, which both closes the ring with the amino acid at position 6 and establishes a ureido link with the amino acid in position 1, giving rise to a side chain. Positions 4 and 5 are typically occupied by aromatic and methylated amino acids, respectively. Position 3 has been reported to be occupied primarily by valine or isoleucine/leucine and less frequently by methionine \[[@B3-marinedrugs-13-03892]\]. Various biological activities have been described for these structures, including inhibition of protein phosphatase \[[@B49-marinedrugs-13-03892]\], carboxypeptidases A \[[@B50-marinedrugs-13-03892],[@B51-marinedrugs-13-03892]\] and U \[[@B52-marinedrugs-13-03892]\], and other protease inhibitory activity \[[@B53-marinedrugs-13-03892]\]. To date, 30 anabaenopeptins have been isolated from many different cyanobacteria genera \[[@B8-marinedrugs-13-03892],[@B54-marinedrugs-13-03892]\] (*Anabaena* \[[@B55-marinedrugs-13-03892],[@B56-marinedrugs-13-03892]\], *Aphanizomenon* \[[@B51-marinedrugs-13-03892]\], *Lyngbya* \[[@B57-marinedrugs-13-03892]\], *Microcystis* \[[@B58-marinedrugs-13-03892]\], *Oscillatoria* \[[@B53-marinedrugs-13-03892],[@B59-marinedrugs-13-03892]\], *Planktothrix* \[[@B60-marinedrugs-13-03892]\], and *Schizothrix* \[[@B61-marinedrugs-13-03892]\]) and also from marine sponges \[[@B62-marinedrugs-13-03892],[@B63-marinedrugs-13-03892]\].

The detected anabaenopeptins could be grouped according to their structural features. Among these compounds, 10 anabaenopeptins that shared similar structural characteristics were detected in *Desmonostoc* sp. CENA360 and *Brasilonema* sp. CENA386 (**12**--**17**, **22**, **25**--**27**). The representative fragmentation pathways and spectra of these compounds are described in [Figure 3](#marinedrugs-13-03892-f003){ref-type="fig"} and [Figure 4](#marinedrugs-13-03892-f004){ref-type="fig"}, and the assignments of the principal ions are shown in [Table 6](#marinedrugs-13-03892-t006){ref-type="table"}, [Table 7](#marinedrugs-13-03892-t007){ref-type="table"}, [Table 8](#marinedrugs-13-03892-t008){ref-type="table"} and [Table 9](#marinedrugs-13-03892-t009){ref-type="table"}. Since the nature of the exocyclic amino acid varies among them, two different fragmentation patterns were observed for these compounds depending on the nature of the amino acid side chain. Extensive fragmentation was observed due to the absence of polar and basic residues in this chain. These anabaenopeptins commonly incorporate the amino acid *N*-methyl asparagine (*N*-MeAsn) in position 5, and on several occasions, either methylation or ethylation was postulated for the homovariant amino acid in position 4.

![Predicted fragmentation pattern for compound **12**.](marinedrugs-13-03892-g003){#marinedrugs-13-03892-f003}

![Product ion spectra for \[M + H\]^+^ of compound **14** at (**a**) CE: 35 eV; (**b**) CE: 50 eV; and (**c**) CE: 70 eV; and (**d**) compound **21** at CE 35 eV.](marinedrugs-13-03892-g004){#marinedrugs-13-03892-f004}

marinedrugs-13-03892-t006_Table 6

###### 

Product ion spectra data for compounds **12**, **14**, and **16**.

  Product Ion Assignment ^a^             12 (*m/z*)   14 (*m/z*)   16 (*m/z*)
  -------------------------------------- ------------ ------------ ------------
  Lys fragment                           84.0768      84.0748      84.0760
  MeAsn immonium ion                     101.0702     101.0670     101.0649
  Phe immonium ion                       120.0738     120.0780     120.0793
  *Z* immonium ion                       \- ^b^       148.1125     162.1259
  MeAsn-Phe − CO + H                     248.1406     248.1400     248.1355
  MeAsn-Phe + H                          276.1333     276.1350     276.1320
  CO-Lys-Phe + H                         304.1630     304.1642     \-
  *Z*-MeAsn + H                          \-           \-           318.1750
  Phe-Lys-Ile + H                        \-           387.2375     387.2269
  Lys-Ile-*Z* + H                        \-           \-           429.2842
  *Z*-Ile-Lys + H                        401.2661     415.2674     429.2808
  Ile-*Z*-MeAsn + H                      403.2336     417.2517     431.2620
  Phe-Lys-Ile-*Z* + H                    \-           562.3374     576.3330
  Ile-*Z*-MeAsn-Phe + H                  550.3302     564.3783     578.3556
  Lys-CO-Lys-(Ile-*Z*) + H               575.3576     589.3531     603.3697
  Lys-Ile-*Z*-MeAsn-Phe − NH~3~ + 2H     661.3682     675.3851     689.4008
  Lys-Ile-*Z*-MeAsn-Phe + 2H             678.3934     692.4075     706.4232
  CO-\[Lys-Ile-*Z*-MeAsn-Phe\] + H       704.3712     718.3935     732.4006
  Lys-CO-Lys-(Phe)-(Ile-*Z*) + H         722.4142     736.4312     750.4436
  Lys-CO-\[Lys-Ile-*Z*-MeAsn-Phe\] + H   850.4818     864.4972     878.5122

^a^ *Z* amino acid in the fourth position: Hph for compound **12**, MeHph for **14**, EtHph for **16**; ^b^ - not detected.

marinedrugs-13-03892-t007_Table 7

###### 

Product ion spectra data for compounds **13**, **15**, and **17**.

  Product Ion Assignment ^a^             13 (*m/z*)   15 (*m/z*)   17 (*m/z*)
  -------------------------------------- ------------ ------------ ------------
  Lys related fragment                   70.0544      70.0619      70.0552
  Lys fragment                           84.0706      84.0731      84.0350
  MeAsn immonium ion                     101.0617     101.068      \-
  Phe immonium ion                       120.0679     120.0748     \-
  Arg + H                                175.1205     175.1184     175.1171
  CO-Arg                                 201.0964     201.0966     201.0970
  MeAsn-Phe − CO + H                     \-^b^        248.1435     248.1286
  MeAsn-Phe + H                          \-           276.1298     276.1337
  Phe-Lys-Ile + H                        \-           387.2358     387.2356
  Ile-*Z*-MeAsn + H                      403.7866     417.2410     \-
  Ile-*Z*-MeAsn-Phe + 2H                 \-           564.3384     \-
  Lys-Ile-*Z*-MeAsn-Phe − NH~3~ + 2H     \-           \-           689.3691
  Lys-Ile-*Z*-MeAsn-Phe + 2H             678.4045     692.4084     706.4222
  Arg-CO-Lys-(Phe)-(Ile-*Z*) + H         \-           \-           778.4472
  Arg-CO-\[Lys-Ile-*Z*-MeAsn-Phe\] + H   878.4864     892.5023     906.5196

^a^ *Z* amino acid in the fourth position: Hph for compound **13**, MeHph for **15**, EtHph for **17**; ^b^ - not detected.

marinedrugs-13-03892-t008_Table 8

###### 

Product ion spectra data for compounds **22** and **26**.

  Product Ion Assignment ^a^                   22 (*m/z*)   26 (*m/z*)
  -------------------------------------------- ------------ ------------
  Lys fragment                                 84.0753      84.0768
  Leu immonium ion                             86.0924      86.0924
  MeAsn immonium ion                           101.0695     101.0677
  Phe immonium ion                             120.0810     120.0724
  *Z* immonium ion                             148.1124     162.1273
  MeAsn-Phe − CO + H                           248.1381     248.1369
  MeAsn-Phe + H                                276.1335     276.1326
  CO-Lys-Phe + H                               304.1667     \- ^b^
  Phe-Lys-Ile                                  387.2406     387.2370
  Ile-*Z*-MeAsn + H                            417.2486     431.2661
  *Z*-Ile-Lys + H                              415.2558     \-
  Ile-*Z*-MeAsn-Phe + 2H                       564.3281     \-
  Leu-CO-Lys-Phe                               433.2435     \-
  *CO-Lys-Phe-NMeAsn*                          *431.1872*   \-
  Leu-CO-Lys-*N*MeAsn-Phe − CO + H             533.2997     533.2996
  Leu-CO-Lys-*N*MeAsn-Phe                      561.2995     561.2967
  Leu-CO-Lys-(Ile)-(*N*MeAsn-Phe) − NH~3~+ H   \-           657.3648
  Leu-CO-Lys-(Ile)-(*N*MeAsn-Phe)              674.3823     674.3810
  Leu-CO-Lys-*Z*-*N*MeAsn-Phe                  736.3966     750.4096
  \[Lys-Ile-*Z*-MeAsn-Phe\] + 2H               692.4077     706.4201
  Leu-CO\[Lys-Ile-*Z*-*N*MeAsn-Phe\]           849.4872     863.5028

^a^ *Z* amino acid in the fourth position: MeHph for compounds **22** and EtHph for **26**; ^b^ - not detected.

marinedrugs-13-03892-t009_Table 9

###### 

Product ion spectra data for compounds **25** and **27**.

  Product Ion Assignment ^a^             25 (*m/z*)   27 (*m/z*)
  -------------------------------------- ------------ ------------
  Lys fragment                           84.0714      84.0714
  MeAsn immonium ion                     101.0633     101.057
  Phe immonium ion                       120.0701     120.077
  *Z* immonium ion                       148.1074     162.1336
  MeAsn-Phe − CO + H                     248.1425     248.1362
  MeAsn-Phe + H                          276.1338     276.1333
  CO-Lys-Phe + H                         304.1570     \- ^b^
  Phe-CO-Lys + H                         320.1601     320.1534
  Phe-Lys-Ile + H                        \-           387.2388
  Ile-*Z*-MeAsn + H                      417.2582     \-
  *Z*-Ile-Lys + H                        415.2709     \-
  Phe-CO-Lys-Phe + H                     467.2262     \-
  Phe-CO-Lys-Phe-MeAsn + H               595.2844     595.2842
  Phe-CO-Lys-Phe-MeAsn-*Z* + H           770.3866     \-
  Phe-CO-Lys-(Ile-*Z*)-(MeAsn) + H       736.3827     \-
  Phe-CO-Lys-Ile-*Z*-MeAsn + H           736.3827     \-
  Lys-Ile-*Z*-MeAsn-Phe                  \-           706.4299
  Lys-Ile-*Z*-MeAsn-Phe + 2H             708.3705     708.3720
  CO-\[Lys-Ile-*Z*-MeAsn-Phe\] + H       718.3895     732.4082
  Phe-CO-(Lys-Ile-*Z*)-(Phe) + H         755.3925     767.3730
  Phe-CO-\[Lys-Ile-*Z*-MeAsn-Phe\] + H   883.4695     897.4858

^a^ *Z* amino acid in the fourth position: MeHph for **25** and EtHph for **27**; ^b^ - not detected.

Thus, compound **12** (*m/z* 850.4818 \[M + H\]^+^) was characterized as Lys-CO\[Lys-Ile-Hph-MeAsn-Phe\]. As expected, the presence of Lys in the side chain generated a simple fragmentation pattern. Consequently, just two low intensity series of fragment ions that were assigned to two preferential primary cleavages were observed in the spectrum ([Figure 4](#marinedrugs-13-03892-f004){ref-type="fig"}). However, enough information was generated to allow a tentative interpretation of the spectrum. The preferential fragmentation observed was attributed to the cleavage of the ureido linkage and the opening of the ring and indicated the presence of lysine in the side chain (*m/z* 678.3934). Further amino acid residue losses from this lineal ion (*i.e.*, acylium or similar) yielded a series of ions at *m/z* 550.3302, 403.2336, 304.1630, and 276.1333 (loss of Lys, Phe, Ile/Leu, and Hph, respectively). Another series of less abundant ions that were generated by the loss of *N*-methyl asparagine and phenylalanine was also observed at *m/z* 722.4142 (loss of MeAsn) and 575.3576 (loss of Phe). The dipeptide fragments at *m/z* 304.1630 and 276.1333 determined the partial sequence Hph-MeAsn-Phe and established the isoleucine/leucine at position 3 (*m/z* 403.2336) and the lysine that closed the ring (*m/z* 678.3934). Ions that are typically observed in the low *m/z* region were also present (Lys at *m/z* 84.0768, MeAsn at *m/z* 101.0702, Phe at *m/z* 120.0738).

Compounds **14** and **16**, which exhibited molecular mass increases of 14 and 28 Da, respectively, when compared to the compound at *m/z* 850.4818 \[M + H\]^+^, exhibited similar product ion spectra. Differences that were observed in the fragments containing the amino acid at position 4 suggested that this residue was either methylated (*m/z* 417.2517, 564.3783, 692.4075, and 736.4312) or ethylated (*m/z* 431.2620, 576.3330, 689.4008, and 750.4436). The existence of ions at *m/z* 148.1125 and 162.1213 that were attributed to the *N*-methylhomophenylalanine (*N*-MeHph) and *N*-ethylhomophenylalanine (*N*-EtHph) immonium ions, respectively, also supported these assignments.

Using similar reasoning, the remaining anabaenopeptins were subsequently characterized. Losses of 157 u that were observed for compounds **22** and **26**, losses of 191 u that were observed for compounds **25** and **27**, and losses of 200 u that were observed for compounds **13**, **15**, and **17** were used to identify the amino acid side chain as leucine, phenylalanine, or arginine, respectively. A fragmentation pattern similar to that described in the preceding paragraphs characterized the cyclic structures. As mentioned above, compounds with \[M + H\]*^+^* at *m/z* 878.5122, 892.5023, and 906.5196 exhibited low efficiency fragmentations, which are characteristic of oligopeptides containing strongly basic residues. When the collision energy used for fragmentation was increased to improve efficiency, the abundance of the fragment ions was compromised ([Figure 4](#marinedrugs-13-03892-f004){ref-type="fig"}).

Four additional anabaenopeptins (**18**, **19**, **23**, **24**) were found in *Nostoc* sp. CENA352. Accurate mass measurement, isotopic profiles, and MS/MS spectra were conclusive to distinguish these compounds from previously described anabaenopeptins and characterize these compounds as new variants \[[@B36-marinedrugs-13-03892],[@B53-marinedrugs-13-03892]\]. Structurally, all of these anabaenopeptins incorporated phenylalanine in the side chain position, as evidenced by the loss of a 191-u fragment from the protonated molecules ([Table 10](#marinedrugs-13-03892-t010){ref-type="table"}). Positions 5 and 6 of these four peptides were also conserved and were occupied by *N*-methyl-alanine and homotyrosine respectively. For the homovariant amino acids in position 4, either homophenylalanine (**18**, **19**) or homotyrosine (**23**, **24**) was proposed; for position 3, the commonly reported valine (**18** and **23**) or leucine/isoleucine (**19** and **24**) was proposed. For example, diagnostic low mass fragment ions that were observed in the product ion spectrum of the compound at *m/z* 842.4416 \[M + H\]^+^ (**23**) provided information about the amino acid residues, indicating the presence of lysine (*m/z* 84.0744), *N*-methyl-alanine (*m/z* 114.0515), phenylalanine (*m/z* 120.0736), homophenylalanine (*m/z* 134.0921), and homotyrosine (150.0887), while higher product ions suggested their sequence. Fragment ions at *m/z* 247.1440 and 263.1399 indicated the attachment of *N*-methyl-alanine to both homotyrosine and homophenylalanine, and subsequently established the sequence Val-Hph-MeAla for *m/z* 346.2124 and Lys-Val-Hph for *m/z* 387.2384. Taking into account the reported anabaenopeptins structures, the Phe-CO-\[Lys-Val-Hph-MeAla-Hty\] sequence was reasonably postulated. The intense fragment ion generated by the loss of a homophenylalanine residue at *m/z* 681.3591 and the less intense series of b-ions (*m/z* 596.3041, 497.2381, 320.1602, and 419.2283) were thus comprehensively attributed ([Table 10](#marinedrugs-13-03892-t010){ref-type="table"}).

marinedrugs-13-03892-t010_Table 10

###### 

Product ion spectra data for compounds **18**, **19**, **23**, and **24**.

  Product Ion Assignment ^a^                     18 (*m/z*)   19 (*m/z*)   23 (*m/z*)   24 (*m/z*)
  ---------------------------------------------- ------------ ------------ ------------ ------------
  Lys fragment                                   84.0734      84.0757      84.0744      84.0749
  MeAla + H − CO                                 114.0499     114.0557     114.0515     114.0514
  Phe immonium ion                               \- ^b^       120.0736     120.0736     120.0742
  Hph immonium                                   \-           \-           134.0921     134.0929
  Htyr immonium                                  150.0907     150.0907     150.0887     150.0873
  Hph-MeAla +H                                   \-           \-           247.1440     247.1485
  HTyr-MeAla + H                                 263.1381     263.1394     263.1399     263.1391
  *Y*-*Z*-MeAla + H                              362.2138     376.2236     346.2124     360.2270
  Lys-*Y*-*Z* + H                                403.2366     417.2447     387.2384     401.2544
  MeAla-Hty-Lys-*Y* + H                          490.2942     \-           490.3023     514.3045
  Phe-CO-Lys-*Y* + H                             \-           \-           419.2283     \-
  Phe-CO-Lys + 2H                                \-           \-           320.1602     320.1605
  Phe-CO-Lys-Hty + 2H                            497.2336     497.2298     497.2381     497.2387
  Phe-CO-Lys-*Y*-*Z* + H                         \-           610.3218     *596.3041*   610.3266
  Phe-CO-Lys-Hty-MeAla + 2H                      582.2993     582.2962     582.2918     582.2915
  Lys-*Y*-*Z*-MeAla-Hty                          665.3655     679.3793     649.3720     663.3819
  Lys-*Y*-*Z*-MeAla-Hty + 2H                     667.3786     681.3953     651.3873     665.4013
  Phe-CO-Lys-(*Y*)-(Hty-MeAla) + 2H              681.3604     695.3756     681.3597     695.3756
  CO-\[Lys-*Y*-*Z*-MeAla-Hty\] + H               693.3629     \-           \-           \-
  Phe-CO-\[Lys-*Y*-*Z*-MeAla-Hty\] + H − CO      830.4384     844.4575     814.4502     828.4634
  Phe-CO-\[Lys-*Y*-*Z*-MeAla-Hty\] + H − H~2~O   840.4385     854.4465     824.4377     838.4398
  Phe-CO-\[Lys-*Y*-*Z*-MeAla-Hty\] + H           858.4405     872.4544     842.4416     856.4561

^a^ *Y* amino acid in the third position: Val for compounds **18** and **23** and Ile for **19** and **24**; *Z* amino acid in the fourth position: Hty for **18** and **19** and Hph for **23** and **24**; ^b^ - not detected.

In addition, a pair of unusual tryptophan-containing anabaenopeptins (**20**--**21**) was also detected at *m/z* 803.4417 \[M + H\]^+^ and 803.4425 \[M + H\]^+^, exclusively in the genus *Brasilonema* sp. (CENA360 and CENA382). As this pair of compounds exhibited similar protonated molecules and product ion spectra but differed in retention times, these compounds were classified as diastereoisomers. The structures of these compounds were postulated in accordance with the fragment ions listed in [Table 11](#marinedrugs-13-03892-t011){ref-type="table"}. According to our literature search, prior to our work, the occurrence of tryptophan-containing anabaenopeptins in cyanobacteria was limited to the genus *Tychonema* sp. \[[@B64-marinedrugs-13-03892]\]. The structurally related compounds isolated from this genus, the brunsvicamides A--C, inhibit tyrosine phosphatase B of *Mycobacterium tuberculosis* (MptpB) \[[@B64-marinedrugs-13-03892]\] and are highly selectivity inhibitors for human leukocyte elastase (HLE) \[[@B65-marinedrugs-13-03892]\]. However, those peptides and the compounds reported here differ in their amino acid sequences. Unlike the brunsvicamides, the postulated anabaenopeptins contain tryptophan in position 4 and *N*-methyl-alanine in the methylated amino acid position. The structures of the compounds described in this study are more closely related to a synthetic brunsvicamide analog described by Walther *et al.* \[[@B66-marinedrugs-13-03892]\], which was found to be an inhibitor of carboxypeptidase A. Thus, further biological tests of these compounds are warranted.

marinedrugs-13-03892-t011_Table 11

###### 

Product ion spectra data for compounds **20** and **21**.

  Product Ion Assignment                         20 (*m/z*)   21 (*m/z*)
  ---------------------------------------------- ------------ ------------
  Lys fragment                                   84.0730      84.0721
  MeAla + H − CO                                 114.0519     114.0504
  Phe immonium ion                               120.0833     120.0747
  Trp fragment                                   130.0645     130.0607
  Lys-Ile + H                                    240.1738     240.1752
  Trp-MeAla + H                                  272.1384     272.1429
  Ile-Trp-MeAla + H                              385.2229     385.2238
  CO-Lys-Phe + H                                 320.1599     320.1602
  Val-CO-Lys-Ile + H                             385.2229     385.2211
  CO-Lys-Phe-MeAla + H                           405.2128     405.2084
  Val-CO-Lys-Ile + H                             419.2214     419.2240
  Val-CO-Lys-Phe-MeAla + H                       504.2829     504.2806
  Val-CO-Lys-Phe-Ile + H                         532.3069     532.3204
  Val-CO-Lys-(Ile)-(Phe-MeAla) + H               617.3706     617.3686
  Lys-Ile-Trp-MeAla-Phe + H                      658.3680     658.3493
  Lys-Ile-Trp-MeAla-Phe + 2H                     660.3879     660.3833
  CO-Lys-Ile-Trp-MeAla-Phe + H                   686.3690     686.3681
  Val-CO-Lys-(Ile-Trp)-(Phe) + H--CO~2~          674.3749     674.3970
  Val-CO-\[Lys-Ile-Trp-MeAla-Phe\] + H − CO~2~   759.4538     759.4521
  Val-CO-\[Lys-Ile-Trp-MeAla-Phe\] + H − CO      775.4563     775.4595
  Val-CO-\[Lys-Ile-Trp-MeAla-Phe\] + H − H~2~O   785.4408     785.4278
  Val-CO-\[Lys-Ile-Trp-MeAla-Phe\] + H           803.4417     803.4425

2.3. Cyanopeptolins
-------------------

Eleven new cyanopeptolins with protonated molecules at *m/z* 984.5381 (**29**), 984.5398 (**33**), 998.5531 (**31**), 998.5549 (**35**), 998.5564 (**36**), 1002.5031 (**28**), 1004.4831 (**30**), 1012.5737 (**37**), 1018.5011 (**32**), 1026.5858 (**38**), and 1032.5170 (**34**) were present in the extracts from *Desmonostoc* strains CENA371 and CENA386. Although no single diagnostic fragment ion can be used to identify this family of peptides, series of fragments related to the conserved position 4 (3-amino-6-hydroxy-2-piperidone amino acid (Ahp) could be used to identify these compounds \[[@B23-marinedrugs-13-03892]\]. Under our experimental conditions, doubly charged ions (\[M − H~2~O + 2H\]^2+^) with an abundance comparable to that of protonated molecules were also observed in the mass spectra of all detected cyanopeptolins. MS and MS/MS analyses suggested closely related structures for all of these cyanopeptides ([Table 12](#marinedrugs-13-03892-t012){ref-type="table"}, [Table 13](#marinedrugs-13-03892-t013){ref-type="table"} and [Table 14](#marinedrugs-13-03892-t014){ref-type="table"}). As the most common structural feature, these cyanopeptolins contained *N*-acetyl-proline-glutamine as side chain, with the fifth position occupied by either a dimethylated tyrosine or chlorinated-methylated tyrosine. Valine and leucine alternated in positions 4 and 6.
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###### 

Product ion spectra data for compounds **30**, **32**, **34**, and **37**.

  Product Ion Assignment ^a^                                      30 (*m/z*)   32 (*m/z*)   34 (*m/z*)   37 (*m/z*)
  --------------------------------------------------------------- ------------ ------------ ------------ ------------
  Pro immonium                                                    70.0542      70.0595      70.0571      70.0541
  Val immonium                                                    \-^b^        72.0692      \-           \-
  Leu immonium                                                    \-           \-           86.0900      86.0935
  *N*AcPro immonium                                               112.0695     112.0732     112.0679     112.0679
  *N*AcPro + H                                                    140.0623     140.0773     140.0678     140.0706
  *N*Me-*R*^1^-Tyr immonium                                       184.0572     184.0486     184.0523     164.1052
  Leu-Ahp − H~2~O − CO + H                                        \-           181.1263     181.1290     181.1300
  Leu-Ahp − H~2~O + H                                             209.1239     \-           209.1257     209.1286
  Ac-Pro-Gln + H                                                  268.1207     268.1276     268.1270     268.1271
  Ac-Pro-Gln-Thr − H~2~O + H                                      351.1656     351.1645     351.1638     351.1633
  *N*Me-*R*^1^-Tyr-*X*-Ahp − H~2~O + H                            406.1509     406.1515     420.1648     400.2181
  AcPro-Gln-Thr-Leu − H~2~O + H                                   464.2465     464.2447     464.2467     464.2468
  AcPro-Gln-Thr-Leu-Ahp-*X* − 2H~2~O + H                          \-           \-           \-           672.3922
  AcPro-Gln-Thr-Leu-Ahp-*X* − H~2~O + H                           \-           \-           \-           690.3777
  Thr-Leu-Ahp-*X*-*N*Me-*R*^1^-Tyr-*Z* − H~2~O + 2H               727.0780     733.3705     747.3811     727.4318
  AcPro-Gln-Thr-(Z-*N*Me-*R*^1^-Tyr)-(Leu) + H                    \-           \-           806.3871     786.4305
  AcPro-Gln-Thr-Leu-Ahp-*Z*-*N*Me-*R*^1^Tyr − H~2~O + H           \-           \-           901.4207     881.4576
  AcPro-Gln-\[Thr-Leu-Ahp-*X*-*N*Me-*R*^1^-Tyr-*Z*\] − H~2~O +H   986.4693     1000.4815    1014.5018    994.5553
  AcPro-Gln-\[Thr-Leu-Ahp-*X*-*N*Me-*R*^1^-Tyr-*Z*\] + H          1004.4831    1018.5011    1032.5170    1012.5737

^a^ *X* amino acid in the fourth position: Val for compounds **30** and **32** and Leu for **34**, **36-37**; *Z* amino acid in the sixth position: Val for **30** and **36** and Leu for **32**, **34**, and **37**; *R*^1^: *O*-methyl for compounds **36** and **37**; Cl for compounds **30**, **32**, and **34**; ^b^ - not detected.
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###### 

Product ion spectra data for compounds **29**, **31**, **33**, and **35**--**36**.

  Product Ion Assignment ^a^                                      29 (*m/z*)   31 (*m/z*)   33 (*m/z*)   35 (*m/z*)   36 (*m/z*)
  --------------------------------------------------------------- ------------ ------------ ------------ ------------ ------------
  Pro immonium                                                    \-^b^        \-           \-           \-           70.0563
  Val immonium                                                    \-           \-           \-           \-           \-
  Leu immonium                                                    86.0924      \-           \-           \-           86.0876
  *N*AcPro immonium                                               112.0755     112.0755     112.0755     112.0688     112.0679
  *N*AcPro + H                                                    140.0618     140.0693     140.0693     140.0693     140.0696
  *N*Me-*R*^1^-Tyr immonium                                       164.1024     150.0907     164.1024     164.1024     164.1052
  Leu-Ahp − H~2~O − CO + H                                        181.1353     181.1267     \-           \-           181.1283
  Leu-Ahp − H~2~O + H                                             209.1243     209.1335     \-           209.1244     209.1331
  Ac-Pro-Gln + H                                                  268.1258     268.1258     \-           268.1258     268.1207
  Ac-Pro-Gln-Thr − H~2~O + H                                      351.1645     351.1637     351.1638     351.1658     351.1642
  *N*Me-*R*^1^-Tyr-*X*-Ahp − H~2~O + H                            386.2025     386.2008     386.2064     386.2034     400.2250
  AcPro-Gln-Thr-Leu − H~2~O + H                                   464.2439     464.2464     464.2493     464.2495     464.2549
  AcPro-Gln-Thr-Leu-Ahp-*X* − 2H~2~O + H                          \-           \-           \-           658.3446     \-
  AcPro-Gln-Thr-Leu-Ahp-*X* − H~2~O + H                           \-           \-           \-           \-           \-
  Thr-Leu-Ahp-*X*-*N*Me-*R*^1^-Tyr-*Z* − H~2~O + 2H               699.4064     713.4158     699.4065     713.4195     713.3971
  AcPro-Gln-Thr-(Z-*N*Me-*R*^1^-Tyr)-(Leu) + H                    \-           772.3942     \-           786.4170     \-
  AcPro-Gln-Thr-Leu-Ahp-*X*-*N*Me-*R*^1^Tyr − H~2~O + H           \-           \-           \-           867.4460     867.4647
  AcPro-Gln-\[Thr-Leu-Ahp-*X*-*N*Me-*R*^1^-Tyr-*Z*\] − H~2~O +H   966.5061     980.5489     966.5144     980.5472     980.5382
  Ac-Pro-Gln-\[Thr-Leu-Ahp-*X*-*N*Me-*R*^1^-Tyr-*Z*\] + H         984.5381     998.5531     984.5398     998.5550     998.5564

^a^ *X* amino acid in the fourth position: Val for compounds **29**, **33** and **35** and Leu for **31** and **36**; *Z* amino acid in the sixth position: Val for **29**, **33** and **36** and Leu for **31**, **35** and **37**; *R*^1^: *O*-methyl for compounds **29**, **31**, **33**, **35** and **36**; ^b^ - not detected.
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###### 

Product ion spectra data for compound **28** and **38**.

  Product Ion Assignment ^a^                                    28 (*m/z*)   38 (*m/z*)
  ------------------------------------------------------------- ------------ ------------
  Pro immonium                                                  \- ^b^       \-
  Leu immonium                                                  86.08763     \-
  *Y* immonium                                                  \-           126.0845
  *Y* + H                                                       \-           154.0743
  *N*Me-*R*^1^-Tyr immonium                                     184.0486     164.1060
  Leu-Ahp − H~2~O − CO + H                                      \-           \-
  Leu-Ahp − H~2~O + H                                           209.1239     \-
  *Y*-Gln + H                                                   268.1207     288.1510
  Ac-Pro-Gln-Thr − H~2~O + H                                    321.1521     365.1662
  *N*Me-*R*^1^-Tyr-*X*-Ahp − H~2~O + H                          420.1585     400.2211
  *Y*-Gln-Thr-Leu − H~2~O + H                                   434.2416     478.2652
  *Y*-Gln-Thr-Leu-Ahp-*X* − 2H~2~O + H                          \-           686.5626
  *Y*-Gln-Thr-Leu-Ahp-*X* − H~2~O + H                           \-           \-
  Thr-Leu-Ahp-*X*-*N*Me-*R*^1^-Tyr-*Z* − H~2~O + 2H             \-           727.4402
  *Y*-Gln-Thr-(Z-*N*Me-*R*^1^-Tyr)-(Leu) + H                    \-           800.4147
  *Y*-Gln-Thr-Leu-Ahp-*X*-*N*Me-*R*^1^Tyr − H~2~O + H           \-           \-
  *Y*-Gln-\[Thr-Leu-Ahp-*X*-*N*Me-*R*^1^-Tyr-*Z*\] − H~2~O +H   984.4914     1008.5481
  *Y*-Gln-\[Thr-Leu-Ahp-*X*-*N*Me-*R*^1^-Tyr-*Z*\] + H          1002.5031    1026.5858

^a^ *Y* exocyclic amino acid in position 1: methyl-dehydroproline (Mdhp) for compound **28** and *N*-propanoyl-proline for compound **38**; *X* amino acid in the fourth position: Leu; *Z* amino acid in the sixth position Leu; *R*^1^: Cl for compound **28** and *O*-methyl for compound **38**; ^b^ - not detected.

This family of cyclic peptides with high structural variability featured a ring formed by six amino acids and a side chain of different lengths and composition \[[@B3-marinedrugs-13-03892]\]. An ester bond between the hydroxyl group of the threonine in position one and the carboxyl group of the terminal amino acid cyclizes the ring. The threonine amino acid in position 1 is occasionally replaced by 3-hydroxy-4-methylproline \[[@B67-marinedrugs-13-03892],[@B68-marinedrugs-13-03892]\]. The 3-amino-6-hydroxy-2-piperidone amino acid (Ahp) always occupied position 3, while a methylated aromatic amino acid and other neutral amino acids are found in positions 5 and 6, respectively. The highly variable side chain may contain an aliphatic fatty acid or a glyceric acid, which is attached either directly to the threonine in position 1 or through one or two amino acids \[[@B3-marinedrugs-13-03892]\]. This family of peptides is often described as protease inhibitors \[[@B69-marinedrugs-13-03892],[@B70-marinedrugs-13-03892],[@B71-marinedrugs-13-03892],[@B72-marinedrugs-13-03892],[@B73-marinedrugs-13-03892]\]. Cyanopeptolins have been isolated mostly from *Microcystis* \[[@B71-marinedrugs-13-03892],[@B74-marinedrugs-13-03892],[@B75-marinedrugs-13-03892]\] but also from other genera such as *Lyngbya* \[[@B76-marinedrugs-13-03892],[@B77-marinedrugs-13-03892]\], *Nostoc* \[[@B67-marinedrugs-13-03892],[@B78-marinedrugs-13-03892]\], *Oscillatoria* \[[@B79-marinedrugs-13-03892],[@B80-marinedrugs-13-03892]\], *Planktothrix* \[[@B60-marinedrugs-13-03892],[@B81-marinedrugs-13-03892]\], *Scytonema* \[[@B82-marinedrugs-13-03892]\], or *Symploca* \[[@B72-marinedrugs-13-03892]\].

[Figure 5](#marinedrugs-13-03892-f005){ref-type="fig"} shows the proposed depsipeptide cyclic structure for compound **37** (Ac-Pro-Gln\[Thr-Leu-Ahp-Leu-*N*Me-OMe-Tyr-Leu\]) and its predicted fragmentation pattern. The most abundant ions observed in the product ion spectrum of this compound were attributed to the loss of amino acid residues from the *C*-terminus (*m/z* 881.4576, 690.3777, 464.2468, 351.1633, and 268.1271) of the dehydrated protonated molecule at *m/z* 994.5553. This precursor ion was suggested to be generated by the cleavage of the ester linkage accompanied by the dehydration of the Thr \[[@B34-marinedrugs-13-03892]\]. Further loss of the acetyl-proline-glutamine side chain from this linear ion was also noted (*m/z* 727.4318). Simultaneously, evidence of dehydration at the Ahp position was observed at *m/z* 400.2184 and 786.4305. An inspection of the low *m/z* region of the spectrum also supported the proposed structure, revealing the presence of ions associated with the amino acids Ahp (*m/z* 209.1286 and 181.1300), *N*Me*O*MeTyr (*m/z* 164.1052), AcPro (*m/z* 112.0679 and 140.0703), Leu (*m/z* 86.0979), and Pro (*m/z* 70.0563). To our knowledge, the *N*-acetyl-proline-glutamine side chain has not been

![(**a**) Product ion spectrum for \[M + H\]^+^ of compound **37** and (**b**) its predicted fragmentation pattern. Conditions as described in the experimental section.](marinedrugs-13-03892-g005){#marinedrugs-13-03892-f005}

Comparing the aforementioned data with those obtained for compound **36**, a highly similar structure was deduced. Differences of 14 u in the protonated molecules and a fragment ion at *m/z* 713.3971 in combination with the existence of product ions at *m/z* 464.2549 and 400.2250 indicated that the leucine attributed to position 6 in compound **37** was replaced by valine. In addition, two other isobaric compounds were observed at earlier retention times (**31** at 30.0 min, and **35** at 31.1 min). Structural differences from compound **36** were proposed based on mass data ([Table 13](#marinedrugs-13-03892-t013){ref-type="table"}). Thus, monomethylated tyrosine was suggested for compound **31** (*m/z* 772.3942, 713.3942, and 150.0907) and a valine residue occupying the fourth position instead of the sixth position was suggested for **35** (*m/z* 867.4460, 786.4170, 713.4195, and 164.1024). Furthermore, two other minor compounds (**29** and **33**) with molecular masses 14 Da lower than the compounds mentioned above and with similar product ion spectra were also detected. Based on the mass results (*m/z* 966.5061/966.5144 and 699.4064/699.4065), the incorporation of valine at positions 4 and 6 was postulated for this pair of diastereoisomers. Simultaneously with these compounds, another congener was observed at *m/z* 1026.5858 \[M + H\]^+^ (**38**). Propanoylation of the proline residue instead of the more commonly detected acetylation was suggested for this compound on the basis of its product ion spectrum, which differed in product ions containing the side chain (*m/z* 365.1662, 478.2652, and 686.5626) in combination with the existence of product ions at *m/z* 126.0845 and 154.0743 (attributed to *N*-propanoyl-proline).

Similarly, four additional compounds (**28**, **30**, **32**, and **34**) exhibited fragmentation patterns highly similar to that of compound **37**. While most of the mass spectrum remained conserved, fragment ions containing the original dimethylated tyrosine amino acid exhibited *m*/*z* shifts when compared to that of the model compound. Additionally, the isotopic pattern of these fragment ions in conjunction with that of the protonated molecule revealed the presence of a chlorine atom in their structures. For compound **34**, these fragment ions shifted 20 u (*m/z* 901.4207, 806.3871, 747.3811, 420.1648, and 184.0523), leading us to propose the chlorination of a methylated tyrosine at position 5. For compound **32**, shifts of 20 and 14 u were observed (*m/z* 733.3705, 406.2447, and 184.0486), suggesting that in addition to the modification mentioned above, a substitution of leucine with valine at position 4 also occurred. Based on the same logic, a structure similar to compound **34**, just with the leucine residue at position 6 replaced by valine, was proposed for compound **30**. Finally, for compound **28**, differences of 30 u in product ions containing the side chain were observed in comparison to compound **34** (*m/z* 321.1521 and *m/z* 434.2416). Thus, the same cyclic peptide was proposed for compound **28** with the side chain tentatively attributed to methylated-dehydroproline-glutamine (Mdhp-Gln) or other analogs. The chlorinated and methylated tyrosine amino acid proposed for position 5 was quite unusual and has only been observed in a small number of cyanopeptolins \[[@B71-marinedrugs-13-03892],[@B80-marinedrugs-13-03892]\].

The structural similarity of these compounds to other cyanopeptolins with observed protease inhibitory activity warrants further bioactivity assays. Trypsin inhibitory selectivity was suggested to be related to the existence of basic residues adjacent to Ahp, while chymotrypsin selectivity was proposed to be related to hydrophobic residues. Additionally, residues in other positions as side chains or in the fifth position appear to influence this activity \[[@B5-marinedrugs-13-03892],[@B72-marinedrugs-13-03892],[@B83-marinedrugs-13-03892]\]. These assays will be able to establish the influence of the particular properties of these compounds on the selectivity and potency of these and other activities.

3. Experimental Section
=======================

3.1. Strains of Cyanobacteria and Cultivation Conditions
--------------------------------------------------------

The 40 surveyed cyanobacterial strains belong to the culture collection of the Center for Nuclear Energy in Agriculture Collection/University of São Paulo (CENA/USP), Brazil. All strains were isolated from the leaves of four plant species---*Euterpe edulis*, *Guapira opposita*, *Garcinia gardneriana*, and *Merostachys neesii*---that were collected in two regions of the Parque Estadual Serra do Mar (Southeastern Brazil). The isolates (three Choococcales, 13 Pseudanabaenales, and 24 Nostocales) were previously identified using both morphological analysis and phylogenies based on the 16S rRNA gene \[[@B30-marinedrugs-13-03892]\] ([Table 1](#marinedrugs-13-03892-t001){ref-type="table"}). The cultures of cyanobacteria were maintained in liquid BG11 medium under white fluorescent light (30 mmol photons·m^−2^·s^−1^) with a 14:10 h light/dark cycle at 25 ± 1 °C under constant agitation (150 rpm) for 21 days. The cells were then concentrated by centrifugation (7000× *g*, 5 min), washed three times in saline solution (NaCl 0.8%), and re-inoculated into 500-mL flasks containing 200 mL of medium and cultured for a further 21 days.

3.2. Extraction of Peptides
---------------------------

The cell suspensions were concentrated by centrifugation at 7000× *g* for 5 min and lyophilized (SNL216V, Thermo Electron Corporation). The lyophilized cells (10 mg) were extracted three times with 70% methanol via probe sonication (amplitude of 30%, 2 min, Soni Omni Disruptor), centrifuged (9000× *g*, 4 °C, 10 min) and concentrated under a stream of nitrogen (TE-concentrator, Techal). The residue was redissolved in 1 mL of methanol:water (50/50, v/v) for LC/MS analysis.

3.3. LC/MS Analyses
-------------------

Analyses were carried out on a Shimadzu Prominence Liquid Chromatography system coupled to a quadrupole time-of-flight mass spectrometer (Micro TOF-QII; Bruker Daltonics, MA, USA) with an ESI interphase. Separations were achieved using a Luna C18 (2) column (250 mm × inner diameter 3:00, 5 μm) (Phenomenex, Torrance, CA, USA) protected with a guard column of the same material. Samples (5 μL) were eluted using a mobile phase A (water, 0.1% formic acid, and 5 mM ammonia formate) and a mobile phase B (acetonitrile). The gradient increased linearly from 5% to 90% B over 50 min at a flow rate of 0.2 mL/min. The ionization source conditions were as follows: positive ionization, capillary potential of 3500 V, temperature and flow of drying gas (nitrogen) of 5 mL/min and 300 °C, respectively, nebulizer pressure of 35 psi. Mass spectra were acquired using electrospray ionization in the positive mode over the range of *m/z* from 50 to 3000. The Q/TOF instrument was operated in scan and AutoMS/MS mode, performing MS/MS experiments on the three most intense ions from each MS survey scan. Three collision-induced dissociation CID experiments were performed by varying the collision energies from 30 to 70 to produce many fragment ions of high abundance. The collision energies for fragmentation were as follows. Experiment 1: *m/z* 0--500, (a) 35 eV (single charged precursor ions) and (b) 25 eV (doubly charged charge); *m/z* 500--1000, (a) 50 eV and (b) 40 eV; and *m/z* 1000--2000, (a) 70 eV and (b) 50 eV. Experiment 2: *m/z* 0--500 (a) 50 eV and (b) 40 eV; *m/z* 500--1000, (a) 65 eV and (b) 55 eV; and *m/z* 1000--2000; (a) 85 eV and (b) 65 eV. Experiment 3: *m/z* 0--500, (a) 35 eV and (b) 25 eV; *m/z* 500--1000, (a) 65 eV and (b) 55 eV; and *m/z* 1000--2000, (a) 70 eV and (b) 50 eV with a 75--150% collision energy sweep. The mass spectrometer was calibrated externally with a 10 mM sodium formate cluster solution consisting of 10 mM sodium hydroxide and 0.1% formic acid in water-isopropanol 1:1 (v:v*).* The accurate mass data were processed using Data Analysis 4.0 software (Bruker Daltonics, Bremen, Germany) which provided a ranking of possible elemental formulae (EF) by using the SmartFormulaEditorTM. For each EF, error (deviations between the measured and theoretical mass of a given sum formula) and sigma value (comparisons of the theoretical and the measured isotope pattern of a given formula) are calculated \[[@B65-marinedrugs-13-03892]\]. The confirmation of the elemental formula was based on the widely accepted thresholds of 5 ppm and 20 m Sigma. Every experiment was run in triplicate.

3.4. Chemical
-------------

HPLC grade methanol and acetonitrile from J.T. Baker (USA). Ammonium formate and formic acid, both for mass analyses, were obtained from Fluka (Germany).

4. Conclusions
==============

In the present study, liquid chromatography coupled to a quadrupole time-of-flight mass spectrometer and equipped with an ESI interface was successfully applied to study in depth the cyanopeptide composition of 40 cyanobacterial strains from the Brazilian Atlantic Forest. This approach allowed us to tentatively identify 38 peptides, of which 37 had not been previously described in literature, including aeruginosins, anabaenopeptins, and cyanopeptolins. Based on the mass accuracy data in scan and product ion spectra in combination with the isotopic pattern of the deprotonated and product ions, a planar structure was postulated for each of the detected peptides. In addition to the recently reported aeruginosin 865, 10 novel structural variants were described here. Either hexose or glucuronic acid and butanoic, hexanoic, heptanoic, or octanoic acid *O*-linked to a Choi motif were observed. With respect to anabaenopeptins, this study led to the characterization of 16 anabaenopeptins. Among those anabaenopeptins, two tryptophan-containing anabaenopeptins and 10 additional anabaenopeptins that incorporated the amino acid *N*-methyl asparagine were identified. Furthermore, on several occasions, ethylation was postulated for the homovariant amino acid in position four. With respect to cyanopeptolins, 11 new variants were characterized. An *N*-acetyl proline-glutamine side chain mostly featured these compounds. Additionally, four of these compounds contained the unusual chlorinated *N-*methylated tyrosine. These results highlight the potential of LC-ESI-QTOF-MS for peptide characterization purposes in complex mixtures from small quantities of material. However, the combination of MS to other techniques such as X-ray crystallography or nuclear magnetic resonance (NMR) applied to the pure compounds is necessary for a complete spectroscopic characterization of the proposed peptide structures including the stereochemistry determination.

Among the surveyed strains of cyanobacteria, only nine strains were observed to produce cyanopeptides (three Nostoc sp., two Desmonostoc sp., and four *Brasilonema* sp.). However, a highly diverse array of new peptide variants was revealed in the producer strains, which emphasizes the potential of underexplored environments as a source of bioactive compounds.
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